ABT

SEC source: 0001415889-23-003056 · form4-02232023_120236.xml · derivative · entry 4

Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,648

Underlying: Common Shares · 41,648 shares

Expires 2033-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026.

SEC source: 0001415889-23-003056 · form4-02232023_120236.xml · nonDerivative · entry 1

Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,063

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-003057 · form4-02232023_120200.xml · derivative · entry 3

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,344

Underlying: Common Shares · 48,344 shares

Expires 2033-02-16

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,114 on February 17, 2024, 16,115 on February 17, 2025, and 16,115 on February 17, 2026.

SEC source: 0001415889-23-003057 · form4-02232023_120200.xml · nonDerivative · entry 1

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,867

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-003058 · form4-02232023_120257.xml · derivative · entry 3

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,648

Underlying: Common Shares · 41,648 shares

Expires 2033-02-16

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026.

SEC source: 0001415889-23-003058 · form4-02232023_120257.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,282

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-003060 · form4-02232023_120209.xml · derivative · entry 2

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,803

Underlying: Common Shares · 69,803 shares

Expires 2033-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,267 on February 17, 2024, 23,268 on February 17, 2025, and 23,268 on February 17, 2026.

SEC source: 0001415889-23-003060 · form4-02232023_120209.xml · nonDerivative · entry 1

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,948

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-003064 · form4-02232023_120213.xml · derivative · entry 6

Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,236

Underlying: Common Shares · 31,236 shares

Expires 2033-02-16

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025 and 10,412 on February 17, 2026.

SEC source: 0001415889-23-003064 · form4-02232023_120213.xml · nonDerivative · entry 1

Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,788

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-003068 · form4-02232023_120224.xml · derivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,907

Underlying: Common Shares · 71,907 shares

Expires 2033-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,969 on February 17, 2024, 23,969 on February 17, 2025, and 23,969 on February 17, 2026.

SEC source: 0001415889-23-003068 · form4-02232023_120224.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,637

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-003072 · form4-02232023_120203.xml · derivative · entry 3

Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,812

Underlying: Common Shares · 45,812 shares

Expires 2033-02-16

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,270 on February 17, 2024, 15,271 on February 17, 2025, and 15,271 on February 17, 2026.

SEC source: 0001415889-23-003072 · form4-02232023_120203.xml · nonDerivative · entry 1

Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,162

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-003074 · form4-02232023_120234.xml · derivative · entry 1

Wellisch Alejandro D · CIK 0001717526 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,236

Underlying: Common Shares · 31,236 shares

Expires 2033-02-16

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025, and 10,412 on February 17, 2026.

SEC source: 0001415889-23-003077 · form4-02232023_120232.xml · derivative · entry 3

WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,483

Underlying: Common Shares · 37,483 shares

Expires 2033-02-16

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026.

SEC source: 0001415889-23-003077 · form4-02232023_120232.xml · nonDerivative · entry 1

WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,358

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-000426 · form4-01042023_110134.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,030

Underlying: Common Shares · 71 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-000433 · form4-01042023_110124.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,561

Underlying: Common Shares · 300 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-000437 · form4-01042023_110104.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,949

Underlying: Common Shares · 300 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-000442 · form4-01042023_110134.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,571

Underlying: Common Shares · 300 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-000127 · form4-01032023_100142.xml · nonDerivative · entry 1

Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,462

SEC source: 0001415889-22-012600 · form4-12152022_101206.xml · nonDerivative · entry 1

Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,912

SEC source: 0001415889-22-010919 · form4-10312022_021041.xml · nonDerivative · entry 2

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,873,500

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.82 to $98.67, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-010919 · form4-10312022_021041.xml · nonDerivative · entry 1

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,882,813

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.82 to $97.80, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-010270 · form4-10042022_021021.xml · nonDerivative · entry 1

Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,053

SEC source: 0001415889-22-010261 · form4-10042022_021033.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,918

Underlying: Common Shares · 81 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-010263 · form4-10042022_021015.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,254

Underlying: Common Shares · 341 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-010265 · form4-10042022_021057.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,641

Underlying: Common Shares · 341 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-010267 · form4-10042022_021017.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,233

Underlying: Common Shares · 341 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-009508 · form4-09092022_020900.xml · derivative · entry 3

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 23,008 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-22-009508 · form4-09092022_020900.xml · nonDerivative · entry 2

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,245

SEC source: 0001415889-22-009508 · form4-09092022_020900.xml · nonDerivative · entry 1

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,253

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-009123 · form4-08262022_020840.xml · derivative · entry 4

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,008

Underlying: Common Shares · 23,008 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-22-009123 · form4-08262022_020840.xml · nonDerivative · entry 3

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,245

SEC source: 0001415889-22-009123 · form4-08262022_020840.xml · nonDerivative · entry 2

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,135

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.59 to $105.37, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-009123 · form4-08262022_020840.xml · nonDerivative · entry 1

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Since the date of the reporting person's last ownership report, he transferred 3,738 shares and employee stock options to purchase 69,500 shares in the aggregate to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.

SEC source: 0001415889-22-009126 · form4-08262022_020808.xml · derivative · entry 6

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 56,933 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-22-009126 · form4-08262022_020808.xml · derivative · entry 5

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 45,492 shares

Expires 2024-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-22-009126 · form4-08262022_020808.xml · nonDerivative · entry 3

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,071

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.60 to $105.43, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-009126 · form4-08262022_020808.xml · nonDerivative · entry 2

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244,496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-009126 · form4-08262022_020808.xml · nonDerivative · entry 1

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-008158 · form4-08032022_090813.xml · nonDerivative · entry 1

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,608

SEC source: 0001415889-22-008001 · form4-07272022_020700.xml · nonDerivative · entry 1

Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,503

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.04 to $109.055, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-008020 · form4-07282022_020750.xml · nonDerivative · entry 2

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,923,500

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.33 to $109.85 inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-008020 · form4-07282022_020750.xml · nonDerivative · entry 1

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,945,751

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.32 to $109.31, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-008000 · form4-07272022_020729.xml · nonDerivative · entry 1

Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,868

SEC source: 0001415889-22-007180 · form4-07012022_010747.xml · nonDerivative · entry 1

Calamari Christopher J. · CIK 0001868518 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,089

SEC source: 0001415889-22-007182 · form4-07012022_010722.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,722

SEC source: 0001415889-22-007183 · form4-07012022_010707.xml · nonDerivative · entry 1

Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,121